Winston-Salem, N.C., March 18, 2022 – KeraNetics Inc. announced today that it has been awarded a contract in the amount of $3.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. This contract extends previous work conducted by KeraNetics with BARDA support on the FDA-cleared product KeraStat® Cream.
Winston-Salem, N.C., March 18, 2022 – KeraNetics Inc. announced today that it has been awarded a contract in the amount of $3.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. This contract extends previous work conducted by KeraNetics with BARDA support on the FDA-cleared product KeraStat® Cream.
Dr. Luke Burnett, the CEO and Chief Science Officer at the Company, as well as the Principal Investigator for the project, said “KeraNetics is excited to be working with BARDA on this project. KeraStat® Cream already received FDA clearance for use by cancer patients all over the US for radiation dermatitis. This project seeks to conduct the necessary pivotal studies to expand the product indications in management of Cutaneous Radiation Injury or CRI, which is a more severe condition than most radiotherapy patients experience. Treatments for CRI are also critical to the government’s emergency preparedness efforts against CRI that may result from exposure of the large population to nuclear fallout.”
The research and development in this project will be conducted by KeraNetics’ scientists under the direction of Dr. Burnett in partnership with BARDA. “This work will solve a critical need for the US government and further develop possible medical countermeasures for managing radiation exposure injuries to the skin. The unfortunate events of the last month have reminded us all that radiation injury is still a threat. Additionally, this work will also benefit patients suffering from the often painful skin injuries they experience after radiation therapy, and could redefine the standard of care for this condition. We are grateful to BARDA for the opportunity to conduct this research,” said Dr. Burnett.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50122C00017.
About KeraNetics Inc. – KeraNetics is the global leader in the development and manufacturing of purified keratin medical products. Headquartered in Winston-Salem, NC, KeraNetics is developing first-in-class therapeutic medical products.
For more information visit www.keranetics.com or contact Luke Burnett, CEO and Chief Science Officer. 336-725-0621, [email protected]